16 sep 25   tristel plc - notice of preliminary results tristel plc | tstl | 360 0 0.0% | mkt cap: 171.8m    rns number : 3576z tristel plc 16 september 2025   tristel plc ("tristel" or the "company")   notice of preliminary results analyst & investor briefing schedule   tristel plc (aim: tstl), the manufacturer of infection prevention products, announces that its preliminary results for the year ended 30 june 2025 will be announced on monday 13 october 2025.    analyst briefing   a briefing open to analysts will take place in london on monday 13 october 2025 at 9.30am. to register and for more details please contact walbrook pr on tristel@walbrookpr.com     investor presentation  matt sassone, ceo, and anna wasyl, cfo, will present the company's results in two separate events open to all investors. the same presentation will be given at both events which are being held at different times to offer convenient options for those wishing to attend.    two presentations will take place on monday 13 october 2025 at the following times, the first will be held online via the investor meet company platform and the second will be held in-person in the city of london, full details below:    1.    investor meet company online presentation  tristel management will provide a live online presentation relating to the preliminary results via investor meet company at 11.30am. the presentation is open to all existing and potential shareholders. questions can be submitted pre-event via your investor meet company dashboard up until 9am the day before the meeting or at any time during the live presentation.    investors can sign up to investor meet company for free and add to meet tristel plc via:  https://www.investormeetcompany.com/tristel-plc/register-investor    2.    in-person investor presentation  tristel management will provide an in-person presentation relating to the company's preliminary results at 4.30pm, which is open to all existing and potential shareholders. the company welcomes investors from 4.15pm for a 4.30pm start and will be followed by refreshments.    if you would like to attend, please contact walbrook pr for more details on 020 7933 8780 or email tristel@walbrookpr.com.    the results presentation will be made available on the company's website on the day of results - https://investors.tristel.com/     for further information please contact: tristel plc via walbrook pr matt sassone, chief executive officer https://investors.tristel.com/ anna wasyl, chief financial officer    walbrook pr ltd tel: 020 7933 8780 or tristel@walbrookpr.com paul mcmanus / lianne applegarth / anna dunphy  mob: 07980 541 893/ 07584 391 303/ 07876 741 001     cavendish capital markets ltd tel: 020 7220 0500 geoff nash / callum davidson/trisyia jamaludin (corporate finance)  sunila de silva (corporate broking) / louise talbot (sales)          about tristel plc tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (clo2) chemistry. the company is a market leader in manual decontamination of medical devices, supplying hospitals under the tristel brand, and under the cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.   tristel's head office and manufacturing facility is located in snailwell, near cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. the company targets double digit revenue growth annually and an ebitda margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.   the company has been listed on the london stock exchange's aim market since 2005 (aim: tstl).   for more information about tristel's product range please visit: https://tristel.com   this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   norlammtmttbbfa return to news summary

Label: Neutral